Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus HIPPURAN I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus HIPPURAN I 131.
CERETEC vs HIPPURAN I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical